INTRODUCTION
5-Hydroxytryptamine (5-HT, serotonin) is widely distributed in the serotonergic neurons in the CNS with the cell bodies in the brainstem raphe nuclei. 5-HT is involved in a variety of functions, such as neuronal development, thermoregulation, pain, sleep, appetite, sexual behavior, aggression, anxiety, and mood (36) . It is therefore not surprising that the serotonergic system has been implicated in pathological conditions (e.g., depression, anxiety, psychosis, eating disorders, sexual dysfunctions, and dementia). Much work has accordingly been devoted to develop compounds of potential clinical interest that interact with the serotonergic system and its receptors.
Of the many 5-HT receptors discovered (23), the 5-HT 1A receptor has attracted attention during recent years as a potential target for anxiolytic and antidepressant drugs (23) . The 5-HT 1A receptor was discovered and characterized from biochemical and pharmacological studies of (RS )-8-hydroxy-2-(dipropylamino)tetralin (8-OH-DPAT), which binds with high affinity and selectivity to the 5-HT 1A receptor (4, 19, 22, 29, 44) . The high density of this receptor is found in the raphe nuclei as presynaptic somatodendritic receptors and in hippocampus and neocortex as postsynaptic receptors (47) . The 5-HT 1A receptor is negatively coupled to adenylyl cyclase (10) but also to G i -protein-coupled K + channels (55) .
8-OH-DPAT and other 5-HT 1A agonists induce a characteristic 5-HT 1A receptor syndrome in rats, consisting of forepaw treading, flat body posture, and lower lip retraction (7, 18, 29, 53) . They cause hypothermia (26, 30, 39, 45) , hyperphagia (11) , and changes in male and female sexual behavior in rats (1, 34) . They also induce secretion of several hor-mones [e.g., adrenocorticotropic hormone (ACTH), corticosterone, oxytocin, and prolactin] (5, 6, 37, 38, 41) .
It was observed earlier that some β-adrenoceptor antagonists (e.g., propranolol, pindolol, and alprenolol) have also high affinity for 5-HT 1A receptors and antagonize the biochemical and behavioral effects evoked by 5-HT 1A receptor agonists (43, 50) . However, it soon became evident that these compounds are partial agonists, particularly at the somatodendritic 5-HT 1A receptors (28) . The first 5-HT 1A receptor antagonist described without any intrinsic activity was (S )-5-fluoro-8-hydroxy-2-(dipropylamino)tetralin [(S )-UH-301] (8, 25) . However, it has also considerable potency as a dopamine D 2 receptor agonist and is thus not suitable for studies of 5-HT 1A receptor pharmacology. The highly potent 5-HT 1A 
receptor antagonist, N-{{2-{1-[4-(2-methoxyphenyl)piperazin-yl]}ethyl}}-N-(2-
)cyclohexanecarboxamide trihydrochloride) (WAY-100,635), was then introduced and reported to lack intrinsic activity at the 5-HT 1A receptors (14, 15) . This compound has been very useful in the characterization of 5-HT 1A receptor function.
Recently, we have reported the pharmacological characterization of a novel, highly selective, 5-HT 1A receptor antagonist, (R )-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide hydrogen (2R,3R )-tartrate monohydrate (NAD-299) (35) with the generic name robalzotan. Here we present a review of the preclinical studies hitherto performed with this compound.
PHYSICOCHEMICAL PROPERTIES
Chemically, robalzotan (NAD-299) is (R )-3-N,N-dicyclobutylamino-8-fluoro-3,4-dihydro-2H-1-benzopyran-5-carboxamide hydrogen (2R,3R )-tartrate monohydrate. The synthesis of robalzotan is described in a patent (12) . The chemical structure of robalzotan is shown in Fig. 1 . The molecular weight of robalzotan is 486.5 (in base form, 318.4). It is a white solid substance with a melting point of 171°C to 176°C. The acid dissociation constant pK a is 7.4, and the distribution constant (log P) is 2.5 in octanol/water, all at 25°C. The solubility in water is 70 mg/ml at 25°C, and the optical rotation (α 25 D) of the base is +80°, determined in 1% ethanol. 
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BIOCHEMICAL PHARMACOLOGY
Receptor Pharmacology
In Vitro Receptor Binding Studies
Receptor binding studies have shown that robalzotan is a selective and high-affinity ligand for 5-HT 1A receptors with a K i value of 0.6 nM (35) . The receptor binding profiles of robalzotan and WAY-100,635 are presented in Table 1 . Robalzotan has a 500-fold higher affinity for 5-HT 1A receptors than for all the other 5-HT receptors tested. It has weak affinity for α 1 -, α 2 -, and β-adrenoceptor subtypes, being at least 250 times less potent than for 5-HT 1A receptors. Furthermore, it has much reduced affinity (K i > 0.2 µM) for all the other receptors tested (Table 1 ). In comparison with the 5-HT 1A receptor antagonist WAY-100,635, robalzotan seems to be more selective, since WAY-100,635 binds with higher affinity to D 2 -, D 3 -, and α 1 -adrenergic receptors (35) .
Second Messenger Studies
The antagonist effect of robalzotan on the 5-HT 1A receptors in vitro has been demonstrated using GH 4 ZD10 cells transfected with rat 5-HT 1A receptors. In these cells, robalzotan did not have any effect on cAMP production but completely blocked suppression of vasoactive intestinal polypeptide (VIP)-stimulated cAMP production by 1 µM 5-HT (35) . The estimated K B value for robalzotan in this system was 1 nM which is in good agreement with the K i value of robalzotan (35) . The in vivo labeling of 5-HT 1A receptors in the mouse brain was studied using [ 3 H]robalzotan (52) . [ 3 H]Robalzotan was injected in a tail vein, and the radioactivity in various brain regions was determined. Fifteen min after the injection, more than 90% of the radioactivity in the hippocampus was intact robalzotan. At this time the amount of [ 3 H]robalzotan was highest in the hippocampus followed by the frontal cortex, mesencephalon, hypothalamus, striatum, and cerebellum. Since cerebellum contains very few 5-HT 1A receptors the amount of radioactivity in this region was subtracted from those amounts found in the other regions in order to get a measure of the specific binding to the 5-HT 1A receptors. Specific binding in the frontal cortex and hippocampus was maximum between 10 and 30 min after the injection, and the radioactivity had almost disappeared after 2 h. Saturation kinetics revealed B max values (pM/g, ww) of 19.6 ± 2.0 in the frontal cortex and 38.0 ± 3. 
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Receptor Tissue h The strychnine-sensitive site.
i The strychnine-insensitive site.
TABLE 1 (continued)
. Images with much higher resolution were obtained in WHA using [ 3 H]robalzotan. These studies confirmed the results obtained using [ 11 C]robalzotan. The highest density was found in the neocortical superficial layers (corresponding to layers I and II). There were generally no marked differences in density between cortical regions, with the exceptions of higher density in the enthorinal cortex and lower density in the occipital cortex. A band of weak labeling was seen in the deeper neocortical layers (probably corresponding to layers V and VI). The labeling of human 5-HT 1A receptors with 
Positron Emission Tomography Studies of Robalzotan in the Monkey Brain
The occupancy of 5-HT receptors by robalzotan in the cynomolgus monkey brain was determined with PET technique using [carbonyl-11 C]WAY-100,635 as radioligand (13) . The first monkey was given 0.004 and 0.04 µmol (2 and 20 µg/kg) of robalzotan per kg i.v., and the second was given 0.02 and 0.2 µmol of robalzotan per kg i.v. in separate measurements. Radioactivity in the cerebellum was used as an estimate of free radioligand concentration (F ) in the brain. Specific binding (B ) in the neocortex and the raphe nuclei was defined as the difference between radioactivity in these regions and that in the cerebellum. The B/F ratio was calculated for the time interval between 20 and 40 min after radioligand injection. Central 5-HT 1A receptor occupancy was defined as the percent reduction of B/F as compared with the baseline ratio. In the baseline measurement, the B/F ratio was 6 to 8 for the neocortical regions and about 4 for the raphe nuclei. After pretreatment with robalzotan, the radioactivity in the neocortex and the raphe nuclei was re-duced in a dose-dependent manner. The highest occupancy (70 to 80%) was accordingly calculated for the measurement after i.v. injection of 0.2 µmol of robalzotan per kg. The results indicate that 50% of the 5-HT 1A receptors in the raphe nuclei were occupied at a robalzotan plasma concentration of 3.9 nM/L. The corresponding value for the neocortex was 5.4 nM/L.
It can be concluded that robalzotan binds in a saturable manner to central 5-HT 1A receptors in the primate brain in vivo. The curvilinear function between drug concentrations and 5-HT 1A receptor occupancy can be used to predict suitable doses of robalzotan for initial studies in humans.
Biochemical Studies
Effects on 8-OH-DPAT-induced Suppression of 5-HT Synthesis In Vivo
Antagonism by robalzotan of 8-OH-DPAT-induced suppression of the synthesis of 5-HT measured as the accumulation of 5-hydroxytryptophan (5-HTP) in rats treated with the aromatic amino acid decarboxylase inhibitor, 3-hydroxybenzylhydrazine (NSD1015), has been reported in several studies (2, 35, 40) . Robalzotan dose-dependently antagonized the 8-OH-DPAT-induced suppression of 5-HTP accumulation in the hippocampus, hypothalamus, striatum, and frontal cortex (35, 40) . It was 3 to 5 times less potent than WAY-100,635 in this respect (40) . Interestingly, both antagonists were more potent in antagonizing the 8-OH-DPAT effect in the hippocampus than in hypothalamus, striatum, and frontal cortex in the order mentioned (40) . It was suggested that this differential regional action may be due to a lower amount of spare receptors in the median raphe nucleus, mainly innervating the hippocampus and in part the hypothalamus, compared with the dorsal raphe nucleus, mainly innervating the striatum and frontal cortex.
Robalzotan was devoid of any 5-HT 1A receptor agonist effect on the 5-HTP accumulation at doses up to 31 µM/kg s.c. and is accordingly a true antagonist of somatodendritic 5-HT 1A receptors in vivo when determined with this technique (35) .
Robalzotan and WAY-100,635 did not significantly increase the 5-HTP accumulation, which indicates a low tone on the somatodendritic 5-HT 1A receptors under the experimental conditions used (35) . However, Ahlenius et al. (2) found that robalzotan significantly increased (about 17%) the 5-HTP accumulation in nucleus accumbens but not in the dorsolateral striatum. This increase in the 5-HTP accumulation was further enhanced when the rats were walking on a treadmill. These results indicate state-dependent effects of robalzotan on the 5-HT synthesis in the ventral limbic forebrain of the rat.
Effects on the Dopamine System In Vivo
Robalzotan had no effect on 3,4-dihydroxyphenylalanine (DOPA) accumulation in the striatum and hypothalamus at doses up to 31 µM/kg s.c. (35 rats that was activated on a treadmill but not in passive rats. The 8-OH-DPAT-induced increase in DOPA accumulation was blocked by robalzotan at doses that block the 5-HT 1A receptors, suggesting that this effect of 8-OH-DPAT was mediated via 5-HT 1A receptor activation (35) . Low doses of WAY-100,635 had a similar effect to that of robalzotan, but a high dose (5.5 µM/kg s.c.) produced a marked increase in the DOPA accumulation in the striatum that probably is due to the D 2 receptor antagonist effect of this compound (35) .
In Vivo Rat Brain Microdialysis Studies
The effects of robalzotan on the output of 5-HT and its main metabolite, 5-hydroxyindoleacetic acid (5-HIAA), in the rat brain were studied in vivo by means of intracerebral microdialysis in awake, freely moving rats, with dialysis probes implanted into the frontal cortex (27) . Given alone, robalzotan (0.2 to 0.6 µM/kg s.c.) did not significantly change the extracellular levels of 5-HT in the frontal cortex. The selective 5-HT 1A receptor agonist 8-OH-DPAT (0.3 µM/kg s.c.) suppressed 5-HT release by almost 80%, an effect completely prevented by pretreatment with robalzotan (0.6 µM/kg s.c.) (Table 3 ). In addition, robalzotan (0.6 µM/kg s.c.), administered 1 h after the selective serotonin reuptake inhibitor (SSRI) citalopram (12 µM/kg s.c.), strongly potentiated the 5-HT-elevating action of the latter compared with controls (citalopram + NaCl). Robalzotan (0.2 to 0.6 µM/kg s.c.) did not per se affect the extracellular levels of 5-HIAA in the frontal cortex.
However, the compound (0.6 µM/kg s.c.) blocked the 8-OH-DPAT (0.25 µM/kg s.c.)-induced reduction of dialysate 5-HIAA (Table 3) . By comparison, the decrease in extracellular 5-HIAA elicited by citalopram (12 µM/kg s.c.) was not significantly affected by robalzotan (0.6 µM/kg s.c.).
In conclusion, the data show that robalzotan displays potent 5-HT 1A autoreceptorblocking properties, as evidenced by its ability to reverse the 5-HT release-suppressing and 5-HIAA-lowering action of the selective 5-HT 1A receptor agonist 8-OH-DPAT. Ro-CNS Drug Reviews, Vol. 5, No. 3, 1999 
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balzotan also antagonizes increases in the endogenous agonist (5-HT) tone at the 5-HT 1A autoreceptors induced by citalopram, thereby markedly enhancing 5-HT elevation in the forebrain cortex.
Electrophysiological Studies
5-HT 1A receptor agonists inhibit the firing of serotonergic dorsal raphe (DR) neurons by an action on somatodendritic autoreceptors (51) . The acute effects of robalzotan alone or in combination with the 5-HT uptake inhibitor, citalopram, on the activity of single 5-HT neurons in the dorsal raphe nucleus of anesthetized rats were studied using extracellular recording technique (3). Administration of robalzotan (0.01 µM/kg i.v.) produced a significant (P < 0.01) increase in the activity of 5-HT cells from 1. In another study using single unit recordings in chloral hydrate-anesthetized rats, robalzotan was compared with 3 other 5-HT 1A receptor antagonists: WAY-100,635, NDL-249, and p-MPPI on the effects on dorsal raphe cell firing (42) . Consistent with a 5-HT 1A receptor antagonist profile, pretreatment with an approximately equimolar (0.02 to 0.03 µM/kg i.v.) dose of each of the four compounds caused a significant rightward shift in the dose-response curve for the 5-HT 1A receptor agonist 8-OH-DPAT (i.v.) ( Table 4 ). The antagonist potency was highest for robalzotan and WAY-100,635, which caused shifts roughly 3 times greater than did either p-MPPI or NDL-249.
In separate studies, each of the antagonists was administered alone in increasing, cumulative doses to evaluate whether it possessed intrinsic agonist activity in this system. At doses below 0.01 µM/kg i.v., none of the drugs altered firing by more than ±20% of basal rate. At higher doses (> 0.1 µM/kg i.v.), robalzotan, WAY-100,635, and NDL-249 caused a dose-dependent suppression of DR cell firing. The ED 50 values were 0.6 ± 0.2 (S.E.M.) µM/kg i.v. for WAY-100,635, 0.7 ± 0.3 µmol/kg i.v. for NDL-249, and 0.9 ± 0.4 µM/kg i.v. for robalzotan. The ED 50 values for inhibition by these drugs were roughly 30 times higher than the doses which antagonized the effects of 8-OH-DPAT. Moreover, the inhibition of firing by all three antagonists, but not the inhibition induced by 8-OH-DPAT, was readily reversed by the norepinephrine releaser d-amphetamine (3.2 mg/kg i.v.), sug-CNS Drug Reviews, Vol. 5, No. 3, 1999 222
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gesting that the inhibitory effects were due to α-adrenergic blockade rather than to 5-HT 1A receptor agonism. It is concluded that the novel 5-HT 1A receptor ligand robalzotan, as well as WAY-100,635, NDL-249, and p-MPPI, fulfills criteria as a 5-HT 1A receptor antagonist lacking intrinsic efficacy at somatodendritic 5-HT 1A autoreceptors. The potency of the novel compound robalzotan was approximately equivalent to that of WAY-100,635 in this electrophysiological assay.
Effects on the 8-OH-DPAT-induced Secretion of Corticosterone in the Rat
Robalzotan has no known effect on plasma corticosterone concentration in the rat (35) . Antagonism of the 8-OH-DPAT-induced secretion of corticosterone in rat plasma was used as a measure of the antagonist effect of a central (hypothalamic) triggered postsynaptic 5-HT 1A receptor response (35) . Robalzotan dose-dependently and competitively antagonized the 8-OH-DPAT-induced increase in plasma corticosterone levels and was about 3 times less potent than was WAY-100,635 in this test (Table 5) .
Effects on the 8-OH-DPAT-induced Hypothermia in the Rat
The hypothermia induced by 8-OH-DPAT (0.75 µM/kg s.c.) in rats is most likely mediated by postsynaptic 5-HT 1A receptors (26, 45 , but see 30). It was blocked by robalzotan and WAY-100,635, the latter being about 7 times more potent than robalzotan (35) . ED 50 values are given in Table 5 . Robalzotan had no known effect on core temperature in the rat.
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Effects on 8-OH-DPAT-Induced Facilitation of Male Rat Ejaculatory Behavior
The facilitation of the male rat ejaculatory behavior induced by 8-OH-DPAT (0.25 to 4 µM/kg s.c.) was fully antagonized by robalzotan (1 µM/kg s.c.) (24) . Robalzotan by itself (0.75 to 3.0 µM/kg s.c.) did not affect the male ejaculatory behavior.
BEHAVIORAL PHARMACOLOGY Effects on Locomotion in Habituated Rats
Wallsten et al. (54) have observed that 5-HT 1A receptor antagonists, albeit at high doses, induce increased locomotion and rearing in rats habituated to the locomotion cage. These effects are blocked by pretreatment of the rats with the tryptophan hydroxylase inhibitor p-chlorophenylalanine, and they are accordingly dependent on endogenous 5-HT. Since the dopamine D 1 and D 2 receptor antagonists (SCH-23390 and raclopride) at doses producing minimal effects by themselves blocked these responses of the 5-HT 1A antagonists, an indirect effect via a dopamine-dependent system seems to be involved. Robalzotan produced a significant increase in the locomotor activity at 3 µM/kg s.c. as did WAY-100,635 at 1.8 µM/kg s.c. (54) .
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Effects on the 8-OH-DPAT-induced Behavioral Syndrome
Robalzotan and WAY-100,635 did not produce any behavioral syndrome in the rat but effectively blocked the 8-OH-DPAT-induced behavioral changes such as lower lip retraction, flat body posture, and forepaw treading (35) . At a dose of 0.03 µM/kg s.c., robalzotan significantly antagonized the flat body posture and forepaw treading produced with 8-OH-DPAT (1.5 µM/kg s.c.), while a higher dose (0.3 µM/kg s.c.) was required to antagonize lower lip retraction, which is the most sensitive response to 8-OH-DPAT of these behavioral effects.
Inhibition of Cage-leaving Response
Rats rapidly leave their home cage if the grid cover is removed (49) . This response is inhibited by 8-OH-DPAT, probably as a result of hind leg abduction which is a part of the behavioral syndrome. Robalzotan antagonized this effect induced by 8-OH-DPAT (0.3 µM/kg s.c.) (35) . The minimal effective doses of robalzotan and WAY-100,635 were 0.3 and 0.05 µM/kg s.c., respectively.
EFFECTS OF SUBCHRONIC TREATMENT
Effect on Receptors
Repeated administration of antidepressant drugs, such as tricyclic antidepressants (TCAs) and SSRIs, has been shown to alter norepinephrine and/or 5-HT transmission and, in some cases, the receptor densities in the brain. To investigate the effects of subchronic treatment with robalzotan on 5-HT 1A , 5-HT 2A , D 2 , and β-adrenergic receptors, male rats were treated twice daily for 21 days with robalzotan (3.1 µM/kg s.c.), the TCAs amitriptyline (96 µM/kg p.o.) and desipramine (33 µM/kg p.o.), the SSRI fluoxetine In agreement with previous reports (48) , subchronic treatment with amitriptyline and desipramine reduced the density of 5-HT 2A and β-adrenergic receptors with no effect on D 2 and 5-HT 1A receptors. Treatment with the 5-HT 1A receptor agonist 8-OH-DPAT re-sulted in downregulation of the 5-HT 2A receptors but not of the other receptors tested. The SSRI fluoxetine and the 5-HT 1A receptor antagonist robalzotan had no effect on the B max of any of the receptors tested. No changes in the affinity constants (K d ) were seen with any of the radioligands used.
In conclusion, similarly to subchronic treatment with fluoxetine, subchronic treatment with robalzotan did not result in any changes in 5-HT 2A and β-adrenergic receptors as seen with the tricyclic antidepressants.
Effect on 5-HT Synthesis and Behavioral Syndrome
Another study has investigated the effects of a 21 days of administration of robalzotan or the reference 5-HT 1A receptor antagonist, WAY-100,635, on the responsiveness of the 5-HT 1A receptor (31) . The following in vivo models were used: rate of 5-HT synthesis, 5-HT turnover, the 5-HT syndrome, and hypothermia. 5-HT 1A agonists, such as 8-OH-DPAT, decrease 5-HT synthesis and 5-HT turnover and induce the 5-HT syndrome and hypothermia when given acutely. 5-HT 1A receptor antagonists block these effects.
Male Sprague-Dawley rats were treated s.c. twice daily for 21 d with saline, robalzotan (0.03, 0.3, and 3 µM/kg, with only the highest dose were given in the 5-HT syndrome and hypothermia experiments), or WAY-100,635 (0.3 µM/kg, 5-HT synthesis, 5-HT turnover; 0.5 µM/kg, 5-HT syndrome, hypothermia). The decrease in 5-HTP accumulation (synthesis rate) and 5-HT turnover (5-HIAA/5-HT ratio) induced by saline or 8-OH-DPAT (0.09, 0.3, and 0.9 µM/kg s.c.) in rats treated with the decarboxylase inhibitor NSD1015 (100 mg/kg s.c.) was determined 2 days after the last injection. The 5-HT syndrome was scored 1, 2, or 7 days after the last injection, in rats challenged with saline or 8-OH-DPAT (0.38 µM/kg s.c.). The temperature response was measured in rats challenged 2 days after the last injection with saline or 8-OH-DPAT (0.38 or 0.9 µM/kg s.c.).
Robalzotan, pretreated animals tended to have an elevated rate of 5-HT synthesis that was significant for the two lower doses in hypothalamus and striatum and the lowest dose in frontal cortex. WAY-100,635 pretreatment did not cause this effect. 5-HT turnover was not significantly changed by the repeated treatment except for the middle dose of robalzotan, where a significant elevation of the ratio in striatum was noted. The 8-OH-DPAT-induced decrease in 5-HTP accumulation and turnover was the same in all treatment groups. 8-OH-DPAT induced the 5-HT syndrome in all treatment groups. No significant differences in response to the 8-OH-DPAT-induced 5-HT syndrome were noted among any of the chronic treatment groups. 8-OH-DPAT induced a fall in body temperature in all treatment groups. There was no significant change in the sensitivity of long-term robalzotan-or 8-OH-DPAT-treated animals to the hypothermic effect of 8-OH-DPAT..
Thus, long-term treatment with robalzotan or WAY-100,635 did not consistently alter the sensitivity of rats to challenge with 8-OH-DPAT, indicating that there was no change in responsiveness of the 5-HT 1A receptor after subchronic treatment with 5-HT 1A receptor antagonists. 
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PHARMACOKINETICS AND METABOLISM
The pharmacokinetics of robalzotan were studied in male and female rats and dogs using robalzotan labeled with 14 C at the carboxyamide position (16) . Robalzotan was given at 25 and 250 µM/kg to rats and at 5 and 25 µM/kg to dogs as single oral doses. Robalzotan was rapidly absorbed after oral administration, with a t max of 0.1 to 0.3 h (rat) and of 0.8 to 0.9 h (dog). The bioavailability was low to moderate (i.e., 4 to 15% in male rats, 13 to 25% in female rats, and 20 to 40% in dogs, respectively) for the two doses administered. The vast majority (73 to 86%) of the given radioactivity was excreted in urine, with most of the amount within the first 24 h after dosing. Robalzotan was extensively metabolized (because of high first-pass effect) with < 0.3% of the administered dose found in urine as unchanged drug. Besides robalzotan itself, the radioactivity was mainly found in 4 peaks in dog and rat urine. In urine, hydroxylated robalzotan and hydroxylated monodealkylated robalzotan were found, as well as monodealkylated and bisdealkylated robalzotan.
In vitro incubations with mouse, rat, dog, monkey, and human liver S9 fraction resulted in 3 to 4 radioactive peaks per species, with monodealkylated robalzotan as the main metabolite (about 80% in humans). In vitro studies offer great potential for obtaining valuable pharmacokinetic information on new drug candidates before their administration to humans. Such studies may predict intrinsic clearance (CL int ), hepatic clearance (CL H ), and the plasma concentration associated with metabolic saturation (from K m ).
Studies were performed with liver microsomes from rats, dogs, and humans (17) . After determination of the initial metabolic rates at different concentrations of robalzotan, preliminary apparent K m and V max values were obtained from Lineweaver-Burk, Hanes, and Eadie Hofstee plots. These data were used as baseline values in the estimation of the Michaelis-Menten constants using nonlinear regression in a one-enzyme model. The one-enzyme model appeared to work satisfactorily to obtain apparent K m and V max estimations. The obtained kinetic constants were used in the prediction of intrinsic clearance and hepatic clearance over a wide concentration range (0 to 100 µM). The V max values for robalzotan were 2.2, 1.5, and 2.6 nM/min/mg of protein for rats, dogs, and humans, respectively. The corresponding K m values were 23, 50, and 19 µM/L. In vivo data on hepatic clearance were obtained from studies performed in rats and dogs.
GENERAL PHARMACOLOGY
The following general pharmacodynamic effects of robalzotan have been studied (46):
Convulsive and anticonvulsive effects
The effect of robalzotan on pentylenetetrazol (PTZ)-induced threshold seizures and on generalized tonic-clonic seizures induced by electroshock (ES) in mice was tested. Robalzotan in high doses (≥ 1000 µM/kg s.c.) prevents seizure spread in the ES test and raises the seizure threshold in the PTZ test. No effects were found at lower doses. Accordingly, at very high doses robalzotan may decrease focal seizures and prevent their generalization.
Analgesia
The effects of robalzotan were investigated in mice using the tail-flick, hot plate, and formalin tests. Within the dose range tested (0.3 to 30 µM/kg s.c.), robalzotan was without effect. The results suggest that robalzotan lacks pharmacologically relevant effects on pain-induced reflexes and on the perception of continuous pain.
Locomotor activity
Rats were given s.c. injections (0.03 to 30 µM/kg) of robalzotan and then placed individually into activity cages. The photocells of the activity cages utilize a computer-based system to determine the location of the animal at any time. A dose of 30 µmol/kg s.c., but not lower doses, produced significant depression of the locomotor activity.
Cardiovascular, respiratory, and body temperature effects
Administration of robalzotan i.v. (≤ 10 µM/kg) in rats caused no changes in arterial blood pressure, electrocardiogram (ECG) parameters, arterial blood gases, or body temperature. The only effect found was an increase in heart rate. The same effect was found after repeated oral (20 or 300 µM/kg) administration of robalzotan for 10 days to conscious rats. The baroreceptor reflex and the carotid sinus reflex were not affected by robalzotan, except for the vasodepressor-induced baroreceptor reflex which showed an attenuation of the heart rate component. In dogs, single oral (≤ 100 µM/kg) and cumulative intravenous (≤ 10 µM/kg) administration of robalzotan resulted in minor decreases in arterial blood pressure, heart rate, respiratory rate, and body temperature, although no dose-related effects were seen. No changes in the ECG or arrhythmias were observed.
Gastrointestinal system
Robalzotan (1 or 25 µM/kg s.c.) had no effect on the fasting motility pattern of the small intestine in conscious rats. Robalzotan also lacked effect on the cholinergically mediated contraction of the guinea pig ileum in vitro, but it blocked the inhibitory effect of 5-HT and 5-carboxyamidotryptamine on electrical field stimulation-induced contraction.
Evaluation of drug interactions
In rats, robalzotan in a wide range of doses (4 to 100 µM/kg p.o.) had no influence on the latency to sleep and/or the duration of sleep induced by ethanol, chloral hydrate, or zolpidem. Combined i.v. administration of robalzotan and the SSRI paroxetine to conscious rats caused no more cardiovascular, respiratory, or body temperature effects than did robalzotan alone.
In conclusion, the selective 5-HT 1A receptor antagonist robalzotan shows minor general pharmacodynamic effects in studies performed to date. The most obvious effect is a slightly increased heart rate in rats.
CONCLUSION
Various biochemical, pharmacological, and behavioral studies have demonstrated that robalzotan is a very selective and potent true antagonist of 5-HT 1A receptors in the brain.
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Therefore, it is a useful tool for studies of the functional role of 5-HT 1A receptors. Of particular interest are the roles of pre-and postsynaptic 5-HT 1A receptors in the therapeutic effect of SSRIs. Undoubtedly, 5-HT 1A receptor antagonists counteract the SSRI-induced decrease in the cell firing of raphe seronergic neurons and thereby increase the 5-HT concentration at postsynaptic 5-HT receptors. The crucial question is, however, whether postsynaptic 5-HT 1A receptors are involved in mediating the antidepressant action of the SSRIs. Only clinical studies can answer this question. Labeled with 3 H or 11 C robalzotan is also a very suitable ligand for 5-HT 1A receptor binding studies both in vitro and in vivo. Robalzotan is a potential therapeutic agent in the treatment of 5-HT-related diseases (e.g., depression, anxiety, psychosis, and dementia).
